<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187587</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-2015-006</org_study_id>
    <nct_id>NCT03187587</nct_id>
  </id_info>
  <brief_title>Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer</brief_title>
  <official_title>An Open-Label, Comparative Trial to Evaluate the Effect of imILT in Patients With Advanced Disease or Stage IV Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Laserthermia Systems AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Laserthermia Systems AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue.&#xD;
      Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of&#xD;
      thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a&#xD;
      tumor specific immunologic response. In laboratory animals the imILT method has also been&#xD;
      shown to induce a so called abscopal effect. This means that when one tumor is treated with&#xD;
      imILT other, untreated, tumors also decrease in size.&#xD;
&#xD;
      The purpose of this trial is to evaluate efficiency when it comes to local tumor destruction&#xD;
      of the imILT treatment method performed pecutaneously in patients diagnosed with pancreatic&#xD;
      cancer. The purpose is also to investigate the functionality and safety of the method.&#xD;
&#xD;
      This trial is an open-label, double-arm study. Twenty patients diagnosed with pancreatic&#xD;
      cancer will be treated in this trial, ten recieving imILT treatment and ten recieving&#xD;
      standard chemotherapy. The study is estimated to be carried out during a time period of 21&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped in agreement with investigator due to slow recruitment.&#xD;
  </why_stopped>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment effect by radiology</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation by Response Evaluation Criteria in Solid Tumours (RECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence the of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of adverse events and laboratory analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability (user evaluation of instrument)</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of instrument and user questionnaires relating to the ease of use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Neoplasms Pancreatic</condition>
  <arm_group>
    <arm_group_label>imILT treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunostimulating Interstitial Laser Thermotherapy (imILT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chemotherapy treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm recieves chemotherapy treatment as standard care at the clinical study site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>imILT</intervention_name>
    <description>The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.</description>
    <arm_group_label>imILT treatment</arm_group_label>
    <other_name>TRANBERG Thermal Therapy System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy treatment</intervention_name>
    <description>The standard chemotherapy treamtment arm recieves only chemotherapy.</description>
    <arm_group_label>Standard chemotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of non-resectable pancreatic adenocarcinoma by form of either locally&#xD;
             advanced disease (stage II-III) or of stage IV disease with hepatic metastasis&#xD;
             (staging according to UICC 2009)&#xD;
&#xD;
          -  Locally advanced disease shall have a lesion diameter less than 4cm&#xD;
&#xD;
          -  If stage IV disease, the patient shall have only liver metastasis, with less than 5 in&#xD;
             number, each one less than 4 cm in diameter&#xD;
&#xD;
          -  The patient is a candidate for standard chemotherapy (as described at point 5.1)&#xD;
&#xD;
          -  Age between 18 and 80 years, males and females&#xD;
&#xD;
          -  Anticipated compliance with treatment and follow-up&#xD;
&#xD;
          -  Have given informed verbal and written consent to participation in the trial&#xD;
&#xD;
          -  Have stable and adequate haematologic, renal and hepatic functions:&#xD;
&#xD;
               1. Hemoglobin ≥9 g/dL&#xD;
&#xD;
               2. Platelet count ≥75 x 109/L&#xD;
&#xD;
               3. International normalized ratio (INR) ≤1.7&#xD;
&#xD;
               4. WBC count ≥2 x 109/L&#xD;
&#xD;
               5. Absolute neutrophil count (ANC) ≥1 x 109/L&#xD;
&#xD;
               6. Albumin ≥2.8 g/dL, total bilirubin ≤3.0 mg/dL (51.3 μmol/L); ALT, AST ≤5 times&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               7. Serum chemistries sodium, potassium, and calcium within normal limits (WNL)&#xD;
&#xD;
               8. Serum creatinine &lt;2.0 mg/dL or creatinine clearance &gt;60 mL/min according to&#xD;
                  Cockroft-Gault formula&#xD;
&#xD;
          -  At least a part of the tumour can be treated with imILT without damage to&#xD;
             adjacentvital structures&#xD;
&#xD;
          -  Have an ECOG performance status &lt;2 (Karnofsky&gt; 60%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV 1 or 2 positive&#xD;
&#xD;
          -  Active autoimmune disease which is judged to reduce an anti-tumour immune response&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Have known bleeding disorder that cannot be managed accordingly with the protocol&#xD;
             rules, such severe acute or chronic liver failure, other genetic blood diseases not&#xD;
             properly managed prior to treatment or other any disease treated with anticoagulant or&#xD;
             anti-platelet medication that cannot be interrupted prior to treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belarmino Goncalves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Portuguese Oncology Institute of Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Portuguese Oncology Institute of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperthermia, Induced</keyword>
  <keyword>Laser Coagulation</keyword>
  <keyword>Laser Therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

